BOSTON — Biogen says its experimental Alzheimer’s treatment diranersen was associated with a 38% slowing of cognitive decline after two years in people with early-stage disease, adding to interest in therapies that target tau protein rather than only amyloid. The latest findings from the Phase 2 CELIA study were presented at the Clinical Trials on Alzheimer’s Disease conference in Boston on November 17. The company said the lowest tested dose, 60 milligrams administered by spinal injection twice a year, produced the strongest result on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) measure. Reuters reported the results.

Biogen reported that the 60 mg twice-yearly regimen was associated with a 38% relative slowing of decline on the CDR-SB scale at Week 96, corresponding to a 1.09-point treatment difference. The company said the result increased from 26% at 18 months and that the two-year analysis showed greater slowing on five of six measures of cognition, daily function and disease progression. The full data summary is available in Biogen’s November 17 announcement.
The results are promising but remain preliminary. CELIA is a Phase 2 study, and the two-year findings came from an ongoing open-label extension after the original 18-month placebo-controlled period. Biogen compared participants who continued diranersen with people originally assigned to placebo who transitioned into the extension. The company said the placebo-equivalent comparison is intended to help assess longer-term benefit, but the design is not the same as a new two-year, fully blinded placebo-controlled trial.
How Diranersen Targets Tau
Alzheimer’s disease is associated with the abnormal accumulation of two proteins in the brain: amyloid-beta and tau. Tau normally helps stabilise the internal structure of nerve cells, but in Alzheimer’s disease it can become abnormal, form tangles and contribute to the disruption and death of brain cells. Diranersen is an antisense oligonucleotide designed to target the messenger RNA of the MAPT gene, reducing the production of tau protein. Biogen explains the mechanism in its official research update.

The approach differs from approved medicines that target amyloid plaques. By reducing the production of tau, researchers hope to address another major process linked to nerve-cell damage and cognitive decline. The Alzheimer’s Association said the earlier Phase 2 results showed reductions in tau biomarkers and brain tau pathology, while the latest two-year findings add longer-term clinical data. Its CELIA trial explainer describes the treatment’s mechanism and earlier findings.
What The Trial Included
The CELIA study enrolled 416 people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. Participants were assigned to one of three diranersen dosing schedules or placebo during the 18-month controlled phase: 60 mg every six months, 115 mg every six months or 115 mg every three months. None of the participants had previously received anti-amyloid treatment, according to the company’s study description.
At the 18-month assessment, the study did not meet its primary endpoint of demonstrating a dose-response relationship on the CDR-SB scale. However, pre-specified analyses of several cognitive and biomarker measures showed benefits, particularly in the 60 mg group. Biogen said it plans to continue development based on the overall data, while acknowledging that additional trials will be needed to confirm the treatment’s efficacy and safety. The May 2026 Phase 2 results release details the original endpoint and earlier findings.
Side Effects And Safety Monitoring
Biogen said diranersen was generally well tolerated through two years, with no new safety signals reported. The most common side effects included headache and back pain associated with the lumbar puncture used to administer the treatment. A small number of participants experienced confusion, while the company reported no cases of the brain swelling that has been associated with some amyloid-targeting medicines. These are company-reported trial findings and will need continued evaluation in larger studies.
Because diranersen is delivered into the fluid surrounding the spinal cord, treatment requires a medical procedure rather than a simple tablet or routine injection into the arm. Researchers will need to assess whether twice-yearly administration is practical for patients, how long benefits persist, and whether the treatment can be safely used alongside other Alzheimer’s medicines. The Biogen update says the company is discussing the outline of a Phase 3 programme with regulators.
Why The Findings Matter
Most disease-modifying Alzheimer’s medicines that have reached the market focus on amyloid. Diranersen is part of a wider effort to target tau, a protein closely linked with the spread of damage through the brain. If the results are confirmed in a larger trial, the treatment could add another approach for people in the early stages of the disease. Reuters reported that the two-year result was the first to show that reducing tau production could be associated with a measurable slowing of cognitive decline in a clinical trial.
However, the 38% figure should not be interpreted as a 38% improvement in memory or a reversal of Alzheimer’s disease. It refers to a relative difference in the rate of decline on a specific clinical scale compared with a placebo-equivalent group in the extension analysis. The treatment has not been approved for routine use, and people living with Alzheimer’s should not change their medication or seek unapproved treatment based on early trial findings.
HeadlinesXtra Analysis
The new data strengthen interest in tau as a treatment target, particularly because the reported benefit increased between 18 months and two years. The result is notable, but the study’s Phase 2 status and the open-label extension design mean that a larger controlled trial is essential before the findings can be considered definitive. The fact that the original study did not meet its primary dose-response endpoint also deserves attention when interpreting the company’s latest announcement.
For patients and families, the research represents a possible future option rather than an available treatment. The next important milestone will be a Phase 3 trial that can test whether the benefit is reproducible across a larger and more diverse group of participants, while carefully monitoring safety and everyday functioning. HeadlinesXtra will continue to follow developments in Alzheimer’s research and evidence-based healthcare in the Health section.
Sources And Further Reading
- Reuters — Biogen’s anti-tau Alzheimer’s drug benefits increase at two years, November 17, 2026
- Biogen — Diranersen demonstrates increasing clinical benefit at two years
- Biogen — Topline results from the Phase 2 CELIA study
- Alzheimer’s Association — Phase 2 CELIA clinical trial results